Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.

Gregor P, Huang QD, Gallardo HF, Rasalan TS, Morris MJ.

Clin Genitourin Cancer. 2012 Jun;10(2):126-9. doi: 10.1016/j.clgc.2011.12.002. Epub 2012 Jan 27. No abstract available.

2.

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S.

Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8. doi: 10.1073/pnas.1110814108. Epub 2011 Sep 20.

3.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD.

Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Review.

4.

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD.

Clin Cancer Res. 2010 Aug 1;16(15):4057-65. doi: 10.1158/1078-0432.CCR-10-1093. Epub 2010 Jul 20.

5.

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD.

Cancer Immun. 2010 Jan 7;10:1. Erratum in: Cancer Immun. 2010 Feb 24;10:5. Ritter, Erika [added].

6.

Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J.

Cytotherapy. 2009;11(7):912-22. doi: 10.3109/14653240903136987.

7.

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD.

Cancer Immun. 2009 Jun 5;9:5.

8.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.

9.

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, Krown SE, Livingston PO, Ejadi S, Panageas KS, Engelhorn ME, Terzulli SL, Houghton AN, Wolchok JD.

Mol Ther. 2008 Dec;16(12):2022-9. doi: 10.1038/mt.2008.196. Epub 2008 Sep 16.

10.

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.

Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE, Livingston PO, Heywood M, Riviere I, Panageas KS, Terzulli SL, Perales MA.

Mol Ther. 2007 Nov;15(11):2044-50. Epub 2007 Aug 28.

11.

In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.

Yuan J, Gallardo HF, Rasalan T, Ranganathan R, Wang J, Zhang Y, Panageas K, Stan R, Young JW, Houghton AN, Wolchok JD.

Cytotherapy. 2006;8(5):498-508. Erratum in: Cytotherapy. 2007;9(4):406.

PMID:
17050255
12.

[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.

Zanzonico P, Koehne G, Gallardo HF, Doubrovin M, Doubrovina E, Finn R, Blasberg RG, Riviere I, O'Reilly RJ, Sadelain M, Larson SM.

Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):988-97. Epub 2006 Apr 11.

PMID:
16607546
13.

Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics.

Segal NH, Blachere NE, Guevara-Patiño JA, Gallardo HF, Shiu HY, Viale A, Antonescu CR, Wolchok JD, Houghton AN.

Cancer Immun. 2005 Feb 1;5:2.

14.

Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes.

Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, Larson SM, Tjuvajev JG.

Nat Biotechnol. 2003 Apr;21(4):405-13. Epub 2003 Mar 24.

PMID:
12652311
15.

Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer.

Rovira A, De Angioletti M, Camacho-Vanegas O, Liu D, Rosti V, Gallardo HF, Notaro R, Sadelain M, Luzzatto L.

Blood. 2000 Dec 15;96(13):4111-7.

16.

Retroviral-mediated gene transfer in primary murine and human T-lymphocytes.

Rivière I, Gallardo HF, Hagani AB, Sadelain M.

Mol Biotechnol. 2000 Jun;15(2):133-42.

PMID:
10949826
17.

Rapid selection of antigen-specific T lymphocytes by retroviral transduction.

Koehne G, Gallardo HF, Sadelain M, O'Reilly RJ.

Blood. 2000 Jul 1;96(1):109-17.

18.

Adenovirus facilitated infection of human cells with ecotropic retrovirus.

Scott-Taylor TH, Gallardo HF, Gänsbacher B, Sadelain M.

Gene Ther. 1998 May;5(5):621-9.

20.

Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity.

Szabolcs P, Gallardo HF, Ciocon DH, Sadelain M, Young JW.

Blood. 1997 Sep 15;90(6):2160-7.

22.

Inhibition of HIV-1 in CEM cells by a potent TAR decoy.

Lee SW, Gallardo HF, Gaspar O, Smith C, Gilboa E.

Gene Ther. 1995 Aug;2(6):377-84.

PMID:
7584112
24.

Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.

Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E.

New Biol. 1992 Jan;4(1):66-74.

PMID:
1536832
25.
26.

Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.

Sullenger BA, Gallardo HF, Ungers GE, Gilboa E.

Cell. 1990 Nov 2;63(3):601-8.

PMID:
2225067

Supplemental Content

Loading ...
Support Center